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Abstract Postconditioning and cyclosporine A prevent
mitochondrial permeability transition pore opening pro-
viding cardioprotection during ischemia/reperfusion.
Whether microvascular obstruction is affected by these
interventions is largely unknown. Pigs subjected to coro-
nary occlusion for 1 h followed by 3 h of reperfusion were
assigned to control (n = 8), postconditioning (n = 9) or
cyclosporine A intravenous infusion 10–15 min before the
end of ischemia (n = 8). Postconditioning was induced by
8 cycles of repeated 30-s balloon inflation and deflation.
After 3 h of reperfusion magnetic resonance imaging,
triphenyltetrazolium chloride/Evans blue staining and his-
topathology were performed. Microvascular obstruction
(MVO, percentage of gadolinium-hyperenhanced area) was
measured early (3 min) and late (12 min) after contrast
injection. Infarct size with double staining was smaller in
cyclosporine (46.2 ± 3.1 %, P = 0.016) and postcondi-
tioning pigs (47.6 ± 3.9 %, P = 0.008) versus controls
(53.8 ± 4.1 %). Late MVO was significantly reduced by
cyclosporine (13.9 ± 9.6 %, P = 0.047) but not postcon-
ditioning (23.6 ± 11.7 %, P = 0.66) when compared with
controls (32.0 ± 16.9 %). Myocardial blood flow in the
late MVO was improved with cyclosporine versus controls
(0.30 ± 0.06 vs 0.21 ± 0.03 ml/g/min, P = 0.002) and
was inversely correlated with late-MVO extent (R2 = 0.93,
P \ 0.0001). Deterioration of left ventricular ejection
fraction (LVEF) between baseline and 3 h of reperfusion
was smaller with cyclosporine (-7.9 ± 2.4 %, P = 0.008)
but not postconditioning (-12.0 ± 5.5 %, P = 0.22) when
compared with controls (-16.4 ± 5.5 %). In the three
groups, infarct size (b = -0.69, P \ 0.001) and late MVO
(b = -0.33, P = 0.02) were independent predictors of
LVEF deterioration following ischemia/reperfusion
(R2 = 0.73, P \ 0.001). Despite both cyclosporine A and
postconditioning reduce infarct size, only cyclosporine A
infusion had a beneficial effect on microvascular damage
and was associated with better preserved LV function when
compared with controls.
This study was performed in the Department of Cardiovascular
Sciences, KU Leuven, Belgium and in the Center for Cardiovascular
Research and Development, American Heart of Poland.
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Introduction
Despite complete epicardial blood flow restoration during
primary coronary angioplasty in acute myocardial infarc-
tion, ischemia/reperfusion is associated with cardiomy-
ocyte necrosis and with damage of coronary
microvasculature and interstitial edema [6, 22, 23] which
lead to lack of adequate tissue perfusion referred to as no-
reflow phenomenon [32]. Even a small amount of mi-
crovascular damage can be detected by cardiovascular
magnetic resonance (CMR) as microvascular obstruction
(MVO) which is defined as a dark zone with impaired
contrast wash-in within the high-signal-intensity infarcted
region on early (3–5 min after contrast injection) or late
([10 min post-contrast) gadolinium-enhanced images [5].
The histopathological characteristics of microvascular ob-
struction have been extensively studied [46] and its oc-
currence in patients is associated with scar formation, left
ventricular remodeling and worse clinical outcome [42,
53]. Thus, the reduction of microvascular damage seems to
be an important target for adjunctive treatment besides
reperfusion [24, 31].
The opening of mitochondrial permeability transition
pore (mPTP) is considered a key event in cell death after
ischemia and reperfusion [9, 31]. Mitochondrial perme-
ability transition pore that could not open in the acidic
milieu during ischemia, quickly opens as pH rises back to
the neutral level during reperfusion [2] and leads to col-
lapse of the mitochondrial transmembrane potential, ces-
sation of adenosine triphosphate production and
subsequent cell death [15]. Postconditioning composed of
several brief cycles of ischemia alternating with reperfu-
sion applied immediately after relief of a prolonged
coronary occlusion, prevents mitochondrial permeability
transition pore opening by maintaining acidosis at the
onset of reperfusion [8], triggers complex molecular
pathways in the myocardium and may reduce infarct size
[25, 48, 49, 56]. However, a benefit of postconditioning on
infarct size has not been shown in all animal models [11,
19, 27, 47]. Recently, it has been reported that postcon-
ditioning in patients with myocardial infarction reduces
infarct size [51] and microvascular obstruction [38],
however, in both studies the lower area at risk at baseline
in postconditioning patients and the frequent use of aspi-
ration thrombectomy were potential confounders. More-
over, in large randomized clinical trial postconditioning
applied during primary angioplasty did not improve
reperfusion and clinical outcome [18]. It has been
proposed that cyclosporine can recapitulate the beneficial
effects of postconditioning and a systematic review of
experimental studies has shown that cyclosporine A in-
fused during early reperfusion variably and inconsistently
reduces infarct size [35].
Whether cyclosporine A or postconditioning could also
have a beneficial effect on microvascular damage remains
unknown. Clinical studies in this regard have limitations as
the timing of CMR is not always optimal and correlation to
histology is not possible. Therefore, we sought to investi-
gate whether postconditioning or cyclosporine A infusion
influence microvascular obstruction and its functional
consequences in a pig model of coronary ischemia and
reperfusion. If it turned out that cyclosporine A or post-
conditioning had a beneficial effect on microvascular ob-
struction, a series of additional experiments would be
conducted to study their impact on myocardial edema, re-
gional myocardial blood flow and the size of no-reflow
area.
Methods
Animal preparation
All animals were treated according to National Health
Guide for the Care and Use of Laboratory Animals and the
study was approved by the Animal Care and Use Com-
mittee of the University of Leuven (reference number ECD
P013/2009) and the Ethical Committee of the Institute of
Pharmacology of the Polish Academy of Sciences (refer-
ence number 1111/2014).
Domestic pigs of both genders weighing 30–40 kg have
been used. Pigs were pre-treated for 3 days with amio-
darone (twice a day 200 mg) to reduce life-threatening
arrhythmias. The day before the experiment they received
300 mg of aspirin and 300 mg of clopidogrel. Animals
were pre-medicated with a combination of tiletamine and
zolazepam (Zoletil100, Virbac Switzerland SA) in a dose
of 8 mg/kg intramuscularly (i.m.) and Xylazine 2.5 mg/kg
i.m. (Vexylan, CEVA Sante Animale, Belgium) before
induction of anesthesia with propofol 3 mg/kg intra-
venously (i.v.) (Diprivan 1 %, AstraZeneca Canada Inc)
and remifentanil 1 lg/kg i.v. (Ultiva, GlaxoSmithKline,
UK Ltd). After intubation, anesthesia was maintained with
propofol 10 mg/kg/h i.v. And remifentanil 0.3 lg/kg/min
i.v. During mechanical ventilation the gas mixture, tidal
volume and ventilation rate were adjusted to maintain
physiologic blood gases. Clinical examination including
corneal reflex and response to pain was used to monitor the
adequacy of anesthesia. An 8F catheter was introduced into
the carotid artery to measure blood pressure and to access
coronary arteries for angiography as well as for blood
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sampling. Hemodynamic recordings (Millar) were done at
baseline and every 30 min during ischemia and reperfusion
whereas ECG was continuously monitored. Data were
processed using dedicated recording and analysis software
(LabChart, ADInstruments, Oxford, UK).
The experimental protocol
A first series of animals were randomized to the control
group (n = 8), the postconditioning group (n = 9) or the
cyclosporine A group (n = 8) and were subjected to
60 min of ischemia and 180 min of reperfusion (Fig. 1a).
Myocardial ischemia was induced by balloon inflation in
the left anterior descending coronary artery, immediately
after the origin of the first diagonal branch. In the control
group no additional intervention was performed; in the
postconditioning group 8 cycles of repeated 30-s balloon
inflation and deflation induced no later than 30 s after
index ischemia [27, 47]; in the cyclosporine A group,
cyclosporine A (Sandimmune, Novartis Pharmaceuticals
Co, USA) in a dose of 10 mg per kilogram body weight
was administered as a peripheral i.v. injection between 15
and 10 min prior to the end of myocardial ischemia to
prevent mitochondrial permeability transition pore open-
ing during reperfusion, as previously described [1, 35].
Both left anterior descending artery occlusion and its re-
opening were confirmed by contrast injection. After 3 h of
reperfusion, CMR imaging was performed and then
potassium chloride was given intravenously to induce
cardiac arrest.
As microvascular obstruction was effectively reduced
only with cyclosporine A infusion, using the same protocol
a series of additional experiments was conducted in the
cyclosporine A (n = 8) and control group (n = 8) (Online
Resource 1). In these animals we aimed at elucidating the
mechanisms of MVO reduction with cyclosporine A, by
additionally comparing the size of myocardial edema, re-
gional myocardial blood flow (MBF) as measured by CMR
and the size of no-reflow territory as measured by the de-
fect of thioflavin S staining.
The assessment of arrhythmia and epicardial blood flow
The total time of sustained ([30 s) ventricular tachy-
cardia and occurrence of ventricular fibrillation during
ischemia and reperfusion were recorded. All coronary
angiograms performed at baseline and at 15 min of
reperfusion were analyzed off-line. Epicardial blood flow
in left anterior descending artery as an infarct-related
vessel and left circumflex artery as a non-infarct-related
vessel was evaluated by means of the TIMI (Throm-
bolysis in Myocardial Infarction) and TIMI frame count
scales.
Cardiovascular magnetic resonance acquisition
Cardiovascular magnetic resonance has been performed on
a 3.0-T scanner (Magnetom Trio, a Tim System, Siemens,
Erlangen, Germany) at baseline (on average 2 days before
experiment) and after 3 h of reperfusion. Images were ac-
quired with a phased array body coil wrapped over the
heart, with electrocardiogram gating and during suspended
respiration. After determination of cardiac axes with lo-
calizers, global and regional left ventricular function has
been assessed with cine imaging in a vertical long axis and
horizontal long axis plane as well as a stack of short-axis
planes using a spoiled gradient echo sequence (TURBO-
FLASH) with the following imaging parameters: repetition
time 35.35 ms, echo time 2.47 ms, flip angle 12, field of
view 330 9 268 mm, voxel size 1.7 9 1.7 9 6.0 mm, 40
cardiac phases, bandwidth 450 Hz/Px, thickness of slice
6 mm and gap 0 mm. Following cine sequences, gadoli-
nium-enhanced imaging 3 (early) and 12 min (late) after
contrast injections of 0.2 mmol/kg gadoterate meglumine
(Dotarem, Guerbet, Roissy, France) was performed with a
segmented three-dimensional inversion recovery with a
gradient echo readout. Typical sequence parameters were:
repetition time 2.19 ms, echo time 0.78 ms, flip angle 158,
field of view 350 mm, voxel size 2.0 9 1.4 9 5.0 mm. The
inversion time was modified iteratively to obtain maximal
nulling of normal myocardium. For both cine and contrast-
enhanced imaging, contiguous short-axis slices covered the
entire left ventricle along its long axis from base to apex. In
contrast with the dark-gray signal of the normal my-
ocardium, the microvascular obstruction was identified as a
dark zone, usually located in the subendocardium within the
hyperenhanced, infarcted myocardium, on both early
(3 min post-contrast) and late (12 min post-contrast)
gadolinium-enhanced images (Figs. 1b, 2b, 4a, b) [5].
In additional experiments, apart from above-described
cine and gadolinium-enhanced imaging (Figs. 1b, 2b), T2-
weighted myocardial edema imaging (Fig. 2a) and first-
pass perfusion technique (Fig. 2c) have been performed
with 1.5-T scanner (Signa EXCITE, GE Healthcare, Mil-
waukee, WI, USA) after 3 h of reperfusion. The myocar-
dial edema imaging was performed with the use of breath-
hold, black blood, T2-weighted, double-inversion recovery
fast spin echo sequence. In short-axis orientation, the left
ventricle was entirely encompassed by 8-mm contiguous
slices (Fig. 2a). Typical imaging parameters were: repeti-
tion time: 2 R–R intervals, echo time 62.88 ms, echo train
length 32, field of view 380 9 380 mm, matrix
224 9 224 mm, thickness of slice 8 mm and gap 0 mm.
Subsequently, dual-bolus first-pass perfusion imaging
was performed as previously shown [7, 26, 54]. Briefly,
two gadobutrolum (Gadovist 1 mmol/ml, Bayer Pharma
AG, Germany) doses of 0.0025 and 0.05 mmol/kg of equal
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volume of 10 ml were injected intravenously at a rate of
3.5 ml/s by CMR-compatible contrast injector and flushed
by 20 ml of saline at the same rate. Perfusion slices were
acquired at the two levels of insertion of papillary muscles
to left ventricle and at the top of papillary muscle with s
breath-hold fast gradient echo echo train sequence
(Fig. 2c). Typical sequence parameters were: repetition
time 6.56 ms, echo time 1.38 ms, echo train length 4, flip
angle 20, field of view 400 9 400 mm and matrix
224 9 224 mm.
Fig. 1 Methods. a Study protocol. b Gadolinium-enhanced (GE)
images in short and horizontal long axis. The microvascular
obstruction (indicated by arrows) is a dark zone in the high-intensity
signal of infarct area. The left ventricle landmarks—place of insertion
of papillary muscles (asterisk) and right ventricle (')—have been
used to obtain biopsy specimens from the triphenyltetrazolium
(TTC)-determined infarct territory. c Representative pictures of
TTC/Evans blue staining with indicated place of biopsy correspond-
ing with gadolinium-enhanced area of infarct and microvascular
obstruction. d Microscopic pictures of infarct region with and without
erythrocytes stasis. Black arrows indicate interstitial edema whereas
white arrows show capillaries occupied by erythrocytes
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Cardiac magnetic resonance analysis
All identifiers and image parameters were removed from
the images before analysis. Images were analyzed blinded
and in a random order on a post-processing workstation
with dedicated software (Cardioviewer, KU Leuven,
Belgium).
Cardiac function, infarct size and microvascular
obstruction
The end-diastolic and end-systolic phases were set up as
the phase with the largest and smallest left ventricular
volumes, respectively. Then the endocardial and epicardial
borders were traced on the end-diastolic and end-systolic
images to calculate left ventricular end-diastolic (LVEDV)
and end-systolic (LVESV) volumes from which the left
ventricular ejection fraction (LVEF), stroke volume and
myocardial volume were calculated. Papillary muscles and
trabeculations were included in the left ventricular cavity.
The territory of infarct and microvascular obstruction was
manually delineated on both the early and late gadolinium-
enhanced images and volumes were calculated by multi-
plying the area of delineation with the thickness of the slice
and gap. The mass of infarct, microvascular obstruction
and left ventricle was obtained by multiplying respective
volume by the specific density of myocardial tissue
(1.05 g/ml). The hyperenhanced area of infarct was
Fig. 2 Cardiovascular
magnetic resonance imaging
and histopathology.
Representative pictures of
corresponding: a T2-weighted
myocardial edema,
b hyperenhanced area of infarct
with dark zone of microvascular
obstruction (MVO), c two
perfusion slices of first pass
with contrast medium in the
right ventricle (i), in both
ventricles and myocardium (ii)
and in the left ventricle (iii),
d no-reflow region as a lack of
thioflavin S staining, e the
infarct region determined by
triphenyltetrazolium staining.
*MVO region, **gadolinium-
enhanced infarct area without
MVO, ***border zone,
****remote myocardium
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expressed as percentage of left ventricular mass and mi-
crovascular obstruction as percentage of infarct area. The
area of microvascular obstruction was in the LGE area.
Myocardial edema and regional myocardial blood flow
The territory of myocardial edema was determined in the
same way as infarct area and was expressed as percentage
of left ventricular mass. The regional myocardial blood
flow analysis was described in detail previously [7, 54].
The time-signal intensity curves of LV cavity and the
myocardial regions of interest generated after low and high
contrast dose were used to calculate myocardial blood flow
based on a Fermi function deconvolution method. Using
the same localization of short-axis slices on corresponding
gadolinium-enhanced images 12 min after contrast injec-
tion (Fig. 2b) and the two perfusion slices (Fig. 2c) re-
gional myocardial blood flow in late-MVO region,
gadolinium-hyperenhanced area without MVO, border
zone and remote myocardium was determined.
Histopathology analysis: area at risk, infarct size, no-
reflow region and microscopy
As previously described [36], immediately after heart ex-
cision 2 % Evan’s blue was injected into the coronary ostia
to outline the area at risk. The transversely sectioned left
ventricular slices were incubated with 2,3,5-triphenylte-
trazolium chloride (TTC, 1.4 %) at 37 C to evaluate
myocardial viability. Based on this double staining infarct
territory (non-viable myocardium in the area at risk), bor-
der zone (viable myocardium in the area at risk) and re-
mote myocardium were determined by planimetry using
National Institutes of Health image software by one in-
vestigator blinded to the treatment group and cardiovas-
cular magnetic resonance findings (Fig. 1c). Biopsies from
these three areas were taken in the compared pigs. Addi-
tionally, using left ventricular landmarks (in long axis
place of insertion of papillary muscles, in short-axis place
of insertion of right ventricle) from triphenyltetrazolium-
determined infarct territory, biopsy specimens corre-
sponding with microvascular obstruction and hyperen-
hanced region were collected in 4 pigs from each study
group (Fig. 1c). All biopsies were then fixed in 3 %
paraformaldehyde during 24 h and routinely embedded in
paraffin. 7.5-lm sections were stained with hematoxylin–
eosin, dehydrated and mounted in Depex medium. The
morphometric analysis was performed by two investigators
blinded to the cardiovascular magnetic resonance imaging
data on a Zeiss Axiovert 200 N microscope equipped with
an Axiocam HrC camera. The contribution of cardiac
myocytes, interstitial space and capillaries with erythro-
cytes quantitatively evaluated using Axiovision 4.6
morphometry software (Carl Zeiss, Oberkochen, Germany)
was expressed as a percentage (Fig. 1d).
In a series of additional experiments, before heart ex-
cision 1 ml/kg of 4 % fluorescent thioflavin S dye was
injected via pigtail catheter into the left ventricular cavity.
After heart excision, the left ventricle was sectioned into
8-mm thick short-axis slices. To detect the area without
thioflavin S staining reflecting the no-reflow region, each
slice was viewed under ultraviolet light (Fig. 2d). After-
wards, slices were incubated with TTC (Fig. 2e). The no-
reflow region expressed as the lack of thioflavin S staining
within the TTC territory was determined by planimetry as
above.
Statistical analysis
The study was powered to have a 90 % chance to
demonstrate a 25 % relative reduction of microvascular
obstruction (absolute microvascular obstruction reduction
from 20 to 15 % of infarct size) with a standard deviation
derived from previous studies of B3 % using a P value of
0.05 [5, 36]. To demonstrate such a reduction, 8 pigs were
required in each group.
Statistical analyses were performed with SPSS 20.0
software. For each data set, a box-whisker analysis was
performed. Outliers, i.e. outside the 1.5 times interquartile
range, were removed from the specific dataset and the
derived measurements. Data are expressed as mean
(± standard deviation) or median (interquartile range,
IQR). Continuous variables were first checked for normal
distribution by the Shapiro–Wilk statistics. Analysis of
variance followed by a post hoc Bonferroni test was used to
compare differences of single measurements in the three
groups with normally distributed data whereas non-nor-
mally distributed data were analyzed by Kruskal–Wallis
test and differences between groups were identified using a
test for multiple comparisons of mean ranks. The asso-
ciation between two variables with a normal or non-normal
distribution was assessed by the Pearson or Spearman test,
respectively. Dependent normally or non-normally dis-
tributed variables were compared by t test for paired
samples or Wilcoxon signed-rank test, respectively. Ana-
lysis of variance for repeated measures assuming sphericity
was used to test serial hemodynamic data whereas analysis
of covariance assuming homogeneity of slopes including
the baseline value as a continuous covariate was used to
compare microvascular obstruction, left ventricular func-
tion and epicardial blood flow changes from baseline in the
three groups. The multiple linear regression analysis was
used to determine predictors of LVEF deterioration fol-
lowing ischemia/reperfusion. For the additional ex-
periments involving only controls and cyclosporine A
group, student’s t test or Mann–Whitney U test were
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applied to compare differences between the two groups
with normally or non-normally distributed data, respec-
tively. A two-sided P \ 0.05 was considered statistically
significant.
Results
Clinical and hemodynamic implications of ischemia
and reperfusion
Out of the 25 randomized pigs, one assigned to the post-
conditioning group died at 1 h and 20 min of reperfusion
due to ventricular fibrillation resistant to defibrillation and
was excluded from further analysis. Cyclosporine A, post-
conditioning and control pigs did not differ in body weight
(36.1 ± 3.8, 36.1 ± 2.0 and 37.7 ± 3.6 kg, respectively,
P = 0.53) and gender (male pigs 4/8, 6/8 and 4/8, respec-
tively, P = 0.54). At baseline and at each time point during
ischemia and reperfusion, there were no significant differ-
ences in the three groups with regard to heart rate, systolic,
diastolic and mean blood pressure (Table 1). The total time
of ventricular tachycardia during reperfusion was reduced
by cyclosporine A infusion and postconditioning versus
controls (2.1 ± 1.3 and 1.4 ± 0.6 vs 5.1 ± 0.7 min, re-
spectively, P \ 0.0001 for both treatment groups).
Angiographic characteristics
At baseline all animals had TIMI-3 flow. At 15 min of
reperfusion TIMI-2 flow was found in 2 controls, 4 post-
conditioning and 1 cyclosporine A pig (P = 0.34). After
15 min of reperfusion TFC increased significantly both, in
the infarct-related left anterior descending artery
(P \ 0.01) and in the left circumflex artery (P \ 0.05)
when compared with baseline but no differences were
found between the 3 groups (Table 2).
Myocardial infarct size
There were no differences between cyclosporine A, post-
conditioning and control pigs in the area at risk
(50.2 ± 1.6, 49.8 ± 1.9 and 49.4 ± 2.6 %, respectively,
P = 0.77 of ANOVA, Fig. 3).
Table 1 Hemodynamic data
Min Baseline Ischemia Reperfusion
0 30 60 30 60 90 120 150
Heart rate
Con 99.1 ± 13.0 87.8 ± 18.0 81.8 ± 9.2 101.0 ± 13.9 88.5 ± 21.1 84.0 ± 19.8 79.4 ± 14.0 79.8 ± 18.8
PoC 102.6 ± 17.1 90.4 ± 18.8 90.4 ± 19.4 99.3 ± 19.0 106.0 ± 25.1 96.9 ± 20.6 85.0 ± 11.8 80.0 ± 7.3
CsA 93.2 ± 9.7 88.5 ± 11.1 86.6 ± 10.3 94.1 ± 14.1 91.6 ± 14.4 85.3 ± 13.5 83.8 ± 17.5 87.0 ± 16.0
P value* 0.40 0.95 0.47 0.67 0.22 0.32 0.72 0.55
Systolic blood pressure
Con 100.3 ± 13.4 90.5 ± 12.4 90.5 ± 12.2 90.3 ± 9.8 98.6 ± 7.9 94.5 ± 6.1 91.6 ± 6.1 93.6 ± 5.2
PoC 102.1 ± 10.9 93.8 ± 11.5 97.4 ± 12.7 96.9 ± 7.6 98.3 ± 12.4 96.1 ± 8.1 95.6 ± 7.9 96.4 ± 11.2
CsA 103.6 ± 18.4 92.5 ± 13.2 98.4 ± 12.8 93.5 ± 16.6 96.6 ± 11.9 98.4 ± 14.7 101.3 ± 13.9 101.5 ± 14.9
P value* 0.90 0.87 0.41 0.55 0.93 0.76 0.17 0.38
Diastolic blood pressure
Con 65.6 ± 11.4 62.0 ± 10.8 62.1 ± 11.2 61.0 ± 7.6 67.8 ± 8.7 62.8 ± 4.9 59.9 ± 4.1 61.1 ± 6.2
PoC 68.1 ± 8.4 63.8 ± 9.8 64.0 ± 10.7 62.3 ± 7.6 66.8 ± 10.0 68.1 ± 9.0 66.5 ± 12.1 66.6 ± 12.7
CsA 66.5 ± 12.1 61.6 ± 10.8 65.4 ± 13.5 66.0 ± 14.4 69.3 ± 13.3 66.9 ± 12.2 69.4 ± 9.8 68.6 ± 8.8
P value* 0.90 0.91 0.86 0.61 0.90 0.48 0.14 0.29
Mean blood pressure
Con 80.3 ± 12.4 74.9 ± 11.5 76.3 ± 9.9 73.3 ± 6.8 78.6 ± 8.4 76.9 ± 5.8 76.5 ± 6.5 75.9 ± 5.7
PoC 82.5 ± 9.9 78.6 ± 11.0 79.1 ± 11.5 77.3 ± 6.9 82.4 ± 10.8 79.4 ± 8.1 80.6 ± 10.5 80.5 ± 12.3
CsA 81.6 ± 12.2 77.1 ± 11.5 79.9 ± 11.1 77.0 ± 12.5 79.9 ± 10.5 79.9 ± 11.7 83.5 ± 9.9 82.9 ± 8.8
P value* 0.93 0.80 0.78 0.63 0.75 0.77 0.33 0.33
Data are shown as mean ± standard deviation. ANOVA for repeated measures of differences in the three groups for heart rate: F = 1.38,
df = 14, P = 0.17; systolic blood pressure: F = 0.62, df = 14, P = 0.85; diastolic blood pressure: F = 0.66, df = 14, P = 0.81 and mean
blood pressure: F = 0.25, df = 14, P = 0.99
Con control group (n = 8), PoC postconditioning group (n = 8), CsA cyclosporine A group (n = 8)
* ANOVA for differences in the three groups in a single time point
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Infarct size determined by double staining and expressed
as percentage of area at risk was significantly lower in
cyclosporine A (46.2 ± 3.1 %, P = 0.016) and in post-
conditioning pigs (47.6 ± 3.9 %, P = 0.008) as compared
with control pigs (53.8 ± 4.1 %, Fig. 3). There was also a
trend to a lower hyperenhanced area in cyclosporine A
(24.3 ± 1.4 %, P = 0.20) and postconditioning pigs
(23.0 ± 2.4 %, P = 0.022) versus controls (25.8 ± 1.2 %)
at 12 min after contrast injection.
Microvascular obstruction and its changes
Microvascular obstruction at 3 (early) and at 12 min (late)
after contrast injection was detected in all treated pigs
(Fig. 4a and b, respectively). There were no significant
differences in early MVO in the cyclosporine A, postcon-
ditioning and control groups (31.7 ± 13.9, 42.3 ± 16.2
and 39.1 ± 19.7 %, respectively, P = 0.48 of ANOVA)
(Fig. 4c). Late MVO was significantly smaller in the
cyclosporine A (13.9 ± 9.6 %, P = 0.047) but not in the
postconditioning group (23.6 ± 11.7 %, P = 0.66) when
compared with controls (32.0 ± 16.9 %, Fig. 4c). In the
three groups, late MVO correlated with infarct size as
measured by double staining (R = 0.44, P = 0.038) and
with early MVO (R = 0.76, P \ 0.001). Compared with
control pigs, cyclosporine A infusion was associated with
an absolute reduction of late MVO by 18.1 % (95 % CI
0.8–35.5 %) versus 8.4 % (95 % CI 8.4–25.2 %) for
postconditioning.
Between 3 and 12 min after contrast injection MVO
decreased in the three groups and these changes were in-
dependently associated with treatment assignment
(F = 8.1, df = 2, P = 0.003) and with early MVO
(F = 12.8, df = 1, P = 0.002). The decrease of MVO
between 3 and 12 min after contrast was significantly
higher in cyclosporine A (-17.9 ± 8.4 %, P = 0.02) and
postconditioning (-18.6 ± 11.3, P = 0.009) versus con-
trol pigs (-7.1 ± 4.3, Fig. 4d). The ratio of late-to-early
Table 2 Angiographic data
B R15 D ANCOVA
TIMI frame count in left anterior descending artery
Con 25.5 ± 4.6 31.3 ± 3.8 5.8 ± 2.4 F = 0.98
df = 2
P = 0.39
PoC 23.8 ± 3.2 31.8 ± 6.7 8.0 ± 6.7
CsA 24.0 ± 3.0 29.0 ± 3.1 5.0 ± 1.9
P value* 0.59 0.48 0.36
TIMI frame count in left circumflex artery
Con 21.3 ± 2.0 24.5 ± 1.6 3.8 ± 2.4 F = 2.30
df = 2
P = 0.13
PoC 19.5 ± 2.1 26.8 ± 5.1 7.3 ± 6.6
CsA 19.9 ± 2.8 22.9 ± 2.9 3.0 ± 2.1
P value* 0.37 0.11 0.11
Data are shown as mean ± standard deviation. ANCOVA with baseline value as a continuous covariate for differences between B and R15 in the
three groups
Con control group (n = 8), PoC postconditioning group (n = 8), CsA cyclosporine A group (n = 8), B baseline, R15 15 min of reperfusion,
D difference between R15 and B
* ANOVA for differences in the three groups in a single time point
Fig. 3 The area at risk and infarct size. Area at risk (AAR) by Evans
blue and infarct size by triphenyltetrazolium staining, box plot shows
median and interquartile range (IQR, Q3–Q1). Q1 and Q3 are the first
and third quartiles. Whiskers are drawn at minimum and maximum.
LV left ventricle, Con control group, PoC postconditioning group,
CsA cyclosporine group, *versus controls
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Fig. 4 Microvascular obstruction and its dynamics. Gadolinium-
enhanced (GE) images in short (S) and horizontal long (L) axis
obtained at 3 (early) and 12 (late) min post-contrast. a Representative
pictures of control pig with a small change of microvascular
obstruction (MVO, indicated by arrows) extent by 25 % between 3
and 12 min (infarct size of 27 % of left ventricle). b Representative
pictures of pig pre-treated with cyclosporine A with substantial
decrease of MVO area by 60 % (infarct size of 25 % of left ventricle).
c The early MVO and late MVO. Scatter plot shows absolute values
and means. d The reduction of MVO area between 3 and 12 min post-
contrast, e the late-to-early MVO ratio. Box plot shows median and
interquartile range (IQR, Q3–Q1). Q1 and Q3 are the first and third
quartiles. Whiskers are drawn at minimum and maximum, Con
control group, PoC postconditioning group, CsA cyclosporine group.
*versus controls
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MVO was significantly lower in cyclosporine A
(0.41 ± 0.17, P \ 0.001) and postconditioning
(0.55 ± 0.20, P = 0.008) versus control pigs
(0.82 ± 0.07, Fig. 4e).
Cardiac function and its determinants
Left ventricular volumes, ejection fraction, left ventricular
mass, stroke volume and cardiac output at different time
points are given in Table 3. At 3 h of reperfusion an in-
crease in LVESV and left ventricle mass and a decrease in
LVEDV and cardiac output, without significant inter-group
differences was found. Deterioration of LVEF between
baseline and 3 h of reperfusion was limited by cy-
closporine A infusion (-7.9 ± 2.4 %, P = 0.008) but not
postconditioning (-11.9 ± 5.4 %, P = 0.22) when com-
pared with controls (-16.4 ± 5.5 %, Fig. 5a) (Table 3).
The LVEF deterioration after 3 h of reperfusion was in-
versely correlated with late MVO (Fig. 5b) and infarct size
determined by double staining (Fig. 5c). Adjusted for left
ventricle mass, both infarct size (b = -0.69, 95 % confi-
dence interval for b [-0.34; -0.85], P \ 0.001) as well as
late MVO [b = -0.33, 95 % confidence interval for b
(-0.12; -0.66), P = 0.02] were independent predictors of
Table 3 Cardiac function
B R180 D ANCOVA
LVEDV (ml)
Con 78.0 ± 11.4 61.8 ± 6.4 -16.1 ± 9.8 F = 2.75
df = 2
P = 0.09
PoC 80.1 ± 11.9 71.7 ± 13.4 -8.4 ± 16.5
CsA 78.5 ± 12.4 72.9 ± 11.2 -5.5 ± 5.4
P value* 0.93 0.11 0.21
LVESV (ml)
Con 34.9 ± 5.1 37.7 ± 3.9 2.8 ± 4.5 F = 0.43
df = 2
P = 0.66
PoC 36.2 ± 5.6 40.7 ± 7.2 4.5 ± 6.5
CsA 35.8 ± 5.2 39.0 ± 5.6 3.2 ± 3.4
P value* 0.87 0.58 0.78
LVEF (%)
Con 55.3 ± 2.0 38.9 ± 5.6 -16.4 ± 5.5 F = 5.40
df = 2
P = 0.014
PoC 54.8 ± 1.5 42.9 ± 5.9 -11.9 ± 5.4
CsA 54.2 ± 2.2 46.3 ± 3.5** -7.9 ± 2.4**
P value* 0.59 0.036 0.01
SV (ml)
Con 43.1 ± 6.7 24.1 ± 5.0 -19.0 ± 7.2 F = 4.66
df = 2
P = 0.023
PoC 43.9 ± 6.6 30.9 ± 7.9 -12.9 ± 10.9
CsA 42.6 ± 7.6 33.9 ± 6.7** -8.7 ± 2.8
P value* 0.94 0.027 0.06
CO (ml/s)
Con 71.2 ± 10.9 42.9 ± 6.6 -28.3 ± 4.4 F = 1.31
df = 2
P = 0.29
PoC 72.1 ± 10.9 43.7 ± 6.6 -28.4 ± 4.3
CsA 70.4 ± 12.5 42.6 ± 7.6 -27.7 ± 4.9
P value* 0.96 0.96 0.96
LV mass (g)
Con 59.7 ± 8.8 75.8 ± 12.0 16.2 ± 7.3 F = 1.59
df = 2
P = 0.23
PoC 63.8 ± 5.9 74.6 ± 10.0 10.8 ± 6.6
CsA 63.0 ± 7.4 73.3 ± 8.3 10.3 ± 6.7
P value* 0.52 0.89 0.20
Data are shown as mean ± standard deviation. ANCOVA with baseline value as a continuous covariate for differences between B and R180 in
the three groups
LV left ventricle, LVEDV LV end-diastolic volume, LVESV LV end-systolic volume, LVEF LV ejection fraction, CO cardiac output, SV stroke
volume, Con control group (n = 8), PoC postconditioning group (n = 8), CsA cyclosporine A group (n = 8), B baseline, R180 3 h of
reperfusion, D difference between R180 and B
* ANOVA for differences in the three groups in a single time point, ** P \ 0.05 by post hoc tests versus control group
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LVEF deterioration following ischemia/reperfusion. In to-
tal, the independent variables explained 73 % (P \ 0.001)
of variance associated with LVEF deterioration
immediately after coronary occlusion and reperfusion, in-
cluding 37 % of variance explained only by infarct size and
10 % by late MVO.
Microvascular obstruction versus regional myocardial
blood flow and no-reflow phenomenon
The myocardial edema was similar in both cyclosporine A
and control pigs (48.3 ± 1.5 and 47.7 ± 1.9 %, respec-
tively, P = 0.50) and did not correlate with the size of
early MVO (P = 0.22), late MVO (P = 0.27) and the no-
reflow area (P = 0.12). Cyclosporine A infusion sig-
nificantly improved myocardial blood flow in the late
MVO territory (0.30 ± 0.06 vs 0.21 ± 0.03 ml/g/min,
P = 0.0012) and in the gadolinium-hyperenhanced infarct
area (0.47 ± 0.05 vs 0.35 ± 0.11 ml/g/min, P = 0.017) as
compared with control pigs. Cyclosporine A did not im-
prove MBF in the border zone and in the remote my-
ocardium (Fig. 6a). MBF in the region of late MVO was
inversely correlated with the size of late MVO (Fig. 6b).
There was also inverse correlation between MBF in the GE
area of infarct and the size of GE area of infarct expressed
as percent of myocardial edema (Fig. 6c).
The no-reflow area expressed as the area of lack of
thioflavin S staining within the TTC territory was sig-
nificantly lower in cyclosporine A group as compared with
control pigs (36.9 ± 18.2 and 59.3 ± 16.6 %, respectively,
P = 0.021, Fig. 7a) and was significantly correlated with
the size of early- and late MVO (Fig. 7b). The ratio of late-
to-early MVO shown in Fig. 4e was validated with the
extent of no-reflow area and with the myocardial blood
flow in the late MVO territory. This ratio was significantly
correlated with no-reflow area (R2 = 0.44, P = 0.005,
Fig. 7c) and inversely correlated with MBF in the late
MVO (R2 = 0.61, P \ 0.001, Fig. 7d).
Histopathological findings
The microscopic analysis focused on loss of myocytes,
interstitial edema and signs of capillary stasis. In the infarct
zone, the three groups showed increased edema with re-
duced density of myocytes as compared with the remote
myocardium. Similarly, capillaries filled with erythrocytes
were observed in the infarct zone and only very rarely in
the border zone and remote myocardium. These changes
were seen in all pigs. No significant differences between
the groups were found (Online Resource 2). In all pigs,
microvascular obstruction area was associated with higher
erythrocyte stasis (respective median (IQR) values are 2.4
(0.9–7.5) vs. 0 (0–0.05) %, P \ 0.001) and lower intersti-
tial edema [30.5 (23.5–34.8) vs. 34.0 (26.3–45.5) %,
P = 0.043] as compared with hyperenhanced area (Fig. 8).
Fig. 5 Changes of left ventricular ejection fraction and its determi-
nants. a Changes of left ventricular ejection fraction between baseline
and 3 h of reperfusion (LVEF). Box plot shows median and
interquartile range (IQR, Q3–Q1). Q1 and Q3 are the first and third
quartiles. Whiskers are drawn at minimum and maximum, Con
control group, PoC postconditioning group, CsA cyclosporine A
group, *versus controls. The relationship between: b LVEF and
microvascular obstruction 12 min post-contrast (late MVO) or
c LVEF and infarct size as percentage of area at risk (AAR) as
measured by double staining
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Discussion
The current study demonstrates that cyclosporine A infu-
sion just before restoration of epicardial blood flow pro-
tects against microvascular obstruction as measured in vivo
by cardiovascular magnetic resonance imaging in a pig
model of ischemia and reperfusion. Despite both postcon-
ditioning and cyclosporine A infusion significantly reduced
infarct size and a total time of life-threatening ventricular
arrhythmia, only cyclosporine A was associated with a
better preserved left ventricular function following reper-
fusion. Moreover, cyclosporine A infusion significantly
Fig. 6 Myocardial blood flow.
a Myocardial blood flow (MBF)
in the territory of late
microvascular obstruction
(MVO), gadolinium-
hyperenhanced area without
MVO, border zone and in the
remote myocardium. The
relationship between b MBF in
the region of late MVO and its
size and c MBF in
hyperenhanced area without
MVO and the size of
gadolinium-enhanced area of
infarct. Con control group, CsA
cyclosporine group
Fig. 7 No-reflow area. a No-
reflow area as measured by the
lack of thioflavin S staining
within infarct size (IS) as
measured by
triphenyltetrazolium staining.
The relationship between no-
reflow area and b microvascular
obstruction (MVO) or c late-to-
early MVO ratio and d the
relationship between late-to-
early MVO ratio and
myocardial blood flow in the
late MVO
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reduced no-reflow area and improved regional myocardial
blood flow in the zone of microvascular obstruction and
hyperenhanced area of infarct. Finally, both infarct size and
microvascular obstruction area have been shown to be in-
dependent predictors of left ventricular function dete-
rioration after coronary occlusion and reperfusion.
Postconditioning and cyclosporine A infusion are con-
sidered to have similar cardioprotective effects during I/R
involving inhibition of mPTP opening and preservation of
calcium retention capacity in cardiac myocytes [15–17].
Nevertheless, in contrast to postconditioning, cyclosporine
A does not improve mitochondrial respiration [16]. Cy-
closporine A, however, prevents opening of mPTP by in-
hibition of its interaction with cyclophilin D [3, 39].
Recently a meta-analysis of experimental studies shown
that cyclosporine A reduces infarct size [35] but the results
obtained in studies involving pigs were inconsistent pos-
sibly related to different doses of cyclosporine A
(2.5–10 mg/kg) used [1, 29, 30, 34, 48]. Our data demon-
strate that pretreatment with 10 mg/kg of cyclosporine A
significantly limited infarct size but did not affect the ex-
tent of myocardial edema after 3 h of reperfusion. Our
intention was to produce infarcts with as close as possible
the same area at risk in all treated animals owing to oc-
clusion of left anterior descending artery after the origin of
the first diagonal branch. As a consequence area at risk as
measured by T2-weighted edema in all examined pigs had
small deviation of measurements from mean value. We
have shown that edema was not limited by cyclosporine A
as compared with controls. In contrast, Diaz et al. [10] in a
model of I/R of rabbit cardiomyocytes in cell culture have
found that cyclosporine A protects against cardiac myocyte
necrosis by induction of chloride anions efflux from my-
ocytes enhancing their cell-volume regulatory response
without changes in transmembrane mitochondrial gradient.
We found also that the extent of myocardial edema did not
influence the size of microvascular obstruction and the no-
reflow area. In turn, apart from maintaining acidosis, au-
tacoids released during postconditioning activate survival
signaling pathways including reperfusion injury salvage
kinese pathway [21]. Previous postconditioning protocols
in pigs were composed of 4–8 cycles of repeated 20–30-s
of ischemia and reperfusion [25, 27, 47–49]. We did not
use postconditioning protocol with shorter 20-s cycle of
ischemia and reperfusion requiring open-chest dissection
and cannulation of the coronary artery [25, 48, 49]. Our
closed-chest catheter-based model of I/R does not allow
rapid changes of postconditioning cycles because of the
slowness of the balloon inflations and deflations. Another
postconditioning protocol in pigs with 4 cycles of 30-s of
ischemia and reperfusion did not limit infarct size [27] but
8 cycles of 30-s of ischemia and reperfusion elicited pro-
found reduction of infarct size in Schwartz and Lagranha
study [47] and was also effective in our closed-chest
catheter-based model.
The mechanism of protection against coronary mi-
crovasculature damage associated with postconditioning or
cyclosporine A and its influence on myocardial injury and
left ventricular function remains poorly understood. Fol-
lowing I/R, microvascular perfusion defect despite patency
of epicardial artery known as no-reflow phenomenon is first
a consequence of extensive capillary damage with en-
dothelial cell swelling, large membrane-bound intraluminal
blebs of endothelial cells and cardiomyocyte swelling [32].
Plugging of leukocytes or erythrocytes, intraluminal fibrin
thrombi, endothelial gaps with loss of fluid from capillaries
and extravascular hemorrhage may also contribute to the
microvascular obstruction [32, 46]. However, the effect of
single, lasting a few minutes infusion of cyclosporine A or
several postconditioning cycles on endothelial cell function
and structure, activation of circulating inflammatory cells
and on properties of intraluminal thrombus during acute
phase of myocardial infarction has not been examined so
far. Massoudy et al. [37] have shown that in a model of I/R
of isolated guinea-pig heart, cyclosporine A improved
myocardial post-ischemic function by enhancing nitric
oxide release from endothelium with simultaneous reduc-
tion of oxidative stress. In turn, protection with postcon-
ditioning against I/R injury of human endothelium in the
brachial artery and resistance vessels depended on KATP
Fig. 8 Histological
composition of infarct area with
and without microvascular
obstruction. Data are shown as
mean and absolute values
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channel activation and was mimicked by cyclosporine A
[41]. In our model of I/R of porcine myocardium cy-
closporine A infusion but not postconditioning reduced
significantly microvascular obstruction. Simultaneously,
cyclosporine A improved myocardial blood flow in the late
MVO and reduced the extent of no-reflow phenomenon.
We have shown also that the larger the late microvascular
obstruction, the lower myocardial blood flow in the late
MVO as measured by CMR and the bigger the no-reflow
territory determined by the lack of thioflavin S staining.
Both cyclosporine A infusion and postconditioning ac-
celerated the reduction of microvascular obstruction be-
tween 3 and 12 min after contrast injection, suggesting a
faster contrast penetration due to more preserved mi-
crovascular patency and finally better reperfusion. How-
ever, the effect was more pronounced in cyclosporine
A-treated pigs. The ratio of late-to-early MVO validated
with the extent of no-reflow area and with the myocardial
blood flow in the late-MVO territory, reflects the dynamics
of contrast penetration throughout coronary microcircula-
tion during the early phase of reperfusion. We found that
the lower the ratio of late-to-early MVO the smaller the no-
reflow area and the better myocardial blood flow in late-
MVO territory.
The cause–effect relationship between myocardial and
microvascular injury is still a matter of debate. Ex-
perimental studies indicate that structural changes in the
no-reflow microvasculature are preceded by and limited to
the area of myocyte necrosis [32, 33]. Those findings
suggest that the microvascular damage is not a primary
reason of changes in cardiac myocytes. Simultaneously,
no-reflow regions preceded the presence of macro-
scopically visible hemorrhage in the infarct region [13, 32,
45], however, the influence of damaged microvasculature
on myocardial necrosis remains unclear. On the other hand,
myocardial perfusion in the area at risk, both after 30 as
well as 120 min of ischemia, progressively decreased
within the first 2 h of reperfusion reaching a plateau at
about 50 and 30 % of normal perfusion, respectively [44].
Simultaneously, the extent of no-reflow as measured by the
lack of thioflavin S dye within area at risk increased over
the course of reperfusion from 12 % after 2 min to 31 %
after 2 h and 35 % after 8 h [45]. Moreover the no-reflow
extent was correlated with infarct size after 1 h of reper-
fusion [45] and inversely correlated with residual my-
ocardial perfusion after 4 h [28]. We also observed—
irrespective of treatment assignment—a significant positive
correlation between infarct size and microvascular ob-
struction or no-reflow area, nevertheless our results do not
provide arguments what comes first.
In the clinical settings, infarct size and microvascular
obstruction are important prognostic factors for cardio-
vascular outcome [42, 53]. Their simultaneous predictive
value in determination of left ventricular function recovery
after myocardial infarction is inconsistent. The LVEF at
6-month follow-up in STEMI patients was independently
predicted by myocardial infarct size but not MVO area [4].
In contrast, Wong et al. [52] have shown that only late
MVO was the independent predictor of LVEF at 90 days. It
was also found that both infarct size and microvascular
obstruction predict LVEF in 3–4-month follow-up [12, 40].
Our findings indicate that both infarct size as well as mi-
crovascular obstruction independently and significantly
affected deterioration of LVEF immediately after coronary
occlusion and reperfusion. Moreover, the importance of
infarct size for the prediction of functional deterioration in
acute phase is almost four times bigger than associated
with microvascular obstruction, but the additive protective
effect on both components visible with cyclosporine A
infusion but not with postconditioning was mandatory for
the effective preservation of left ventricular function.
Our study also allowed comparing cardiovascular mag-
netic resonance measurements with pathology findings. We
have found that infarct size measured in vivo by gadoli-
nium enhancement strongly correlated with triphenylte-
trazolium-determined area of infarct. Recently, Robberts
et al. [46] have shown that the contrast-devoid core of
infarct 7 days after induction of myocardial infarction in
pigs contained extensive necrosis with erythrocytes ex-
travasation. We have shown that immediately after 3 h of
reperfusion in the triphenyltetrazolium-positive infarct re-
gion erythrocyte stasis was significantly higher in biopsies
corresponding with a low-signal intensity region of mi-
crovascular obstruction as compared with hyperenhanced
area. These histopathological differences are primarily the
consequence of specific dynamic changes in the infarct
area involving the evolution over time of myocardial
edema and extent of microvascular obstruction [42].
It was shown that postconditioning with 4 cycles of
1-min ischemia and reperfusion prior to primary coronary
angioplasty in patients reduces infarct size [51] and at-
tenuates microvascular obstruction [38]. However, in both
studies postconditioning patients had less myocardial ede-
ma suggesting a lower area at risk at baseline. Moreover, in
60 % of the patients postconditioning was preceded by
aspiration thrombectomy rapidly restoring epicardial flow
and abolishing pH-related protective effects of postcondi-
tioning. In contrast, the same postconditioning protocol
tested in two randomized trials with cardiovascular mag-
netic resonance endpoints [14, 50] was not able to reduce
gadolinium-enhanced infarcted area measured 6–9 days
and 6 months after primary angioplasty. Recently, in the
largest randomized clinical trial to date [18] postcondi-
tioning did not improve ST-segment resolution, myocardial
blush and 30-day clinical outcome. In turn, four or more
inflations during PPCI reduced enzymatic infarct size in
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STEMI patients, but did not translate into improved 4-year
long-term outcomes as compared with patients receiving
1–3 inflations in the infarct-related artery [55]. Small ran-
domized clinical studies showed that cyclosporine infusion
before the opening of infarct-related artery [43] or after
induction of anesthesia for elective cardiac artery bypass
surgery [20] resulted in a significant reduction of enzy-
matic infarct size compared with controls. Our results
suggest that beyond infarct size reduction, the beneficial
effect of cyclosporine A may also be related to better re-
gional myocardial blood flow and preserved left ventricular
function.
In conclusion, in our animal model of ischemia and
reperfusion both cyclosporine A and postconditioning re-
duce infarct size, however, only cyclosporine A infusion
had a beneficial effect on microvascular damage and was
associated with better preserved LV function when com-
pared with controls. Our findings indicate that only si-
multaneous limitation of myocardial and microvascular
injury is associated with functional improvement, there-
fore, we suggest the use of microvascular obstruction as a
surrogate endpoint in future studies in addition to infarct
size.
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